drugset

Drugs / EBV CTL's

Follow last change Dec 2017 re-read 3 minutes ago

EBV CTL's

Developed for: Hodgkins lymphoma · lymphoproliferative syndrome · non-Hodgkin lymphoma
Investigated by: Baylor College of Medicine · Children's National Research Institute · City of Hope Medical Center · Johns Hopkins University · M.D. Anderson Cancer Center · New York Medical College
+3 more
· Ohio University · University of Michigan · University of Utah

Trials 1

today NCT02057445 · Ph 1

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02057445	Jan 2014 → Dec 2016	Hodgkins lymphoma, lymphoproliferative syndrome, non-Hodgkin lymphoma	New York Medical College	Completed	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	EBV CTL's	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02057445 ↗
Modality	Cell therapy	“allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person)” NCT02057445 ↗
Route	Other	“will be infused” NCT02057445 ↗